Rua Bioscience Valuation

Is RUA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RUA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate RUA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate RUA's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for RUA?

Key metric: As RUA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for RUA. This is calculated by dividing RUA's market cap by their current revenue.
What is RUA's PS Ratio?
PS Ratio16x
SalesNZ$316.35k
Market CapNZ$5.08m

Price to Sales Ratio vs Peers

How does RUA's PS Ratio compare to its peers?

The above table shows the PS ratio for RUA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average11.5x
BLT BLIS Technologies
2xn/aNZ$23.0m
CBD Cannasouth
33.9xn/aNZ$32.4m
AFT AFT Pharmaceuticals
1.4x12.4%NZ$284.2m
APLI Appili Therapeutics
8.6xn/aCA$4.2m
RUA Rua Bioscience
16xn/aNZ$5.1m

Price-To-Sales vs Peers: RUA is expensive based on its Price-To-Sales Ratio (16x) compared to the peer average (11.5x).


Price to Sales Ratio vs Industry

How does RUA's PS Ratio compare vs other companies in the Oceanian Pharmaceuticals Industry?

18 CompaniesPrice / SalesEstimated GrowthMarket Cap
RUA 16.0xIndustry Avg. 4.8xNo. of Companies18PS01224364860+
18 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: RUA is expensive based on its Price-To-Sales Ratio (16x) compared to the Oceanic Pharmaceuticals industry average (4.8x).


Price to Sales Ratio vs Fair Ratio

What is RUA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RUA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio16x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate RUA's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies